Cargando…

Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis

Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic role...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Feng, Huang, Qilin, Gong, Zhenyu, Wang, Hongxiang, Chen, Juxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549407/
https://www.ncbi.nlm.nih.gov/pubmed/31213850
http://dx.doi.org/10.2147/OTT.S200755
_version_ 1783424001810366464
author Li, Feng
Huang, Qilin
Gong, Zhenyu
Wang, Hongxiang
Chen, Juxiang
author_facet Li, Feng
Huang, Qilin
Gong, Zhenyu
Wang, Hongxiang
Chen, Juxiang
author_sort Li, Feng
collection PubMed
description Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for these solid cancers. Methods: Publications were searched in PubMed, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang database. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) (AUC) with 95% confidence interval (95% CI) were calculated to evaluate the diagnostic value of circ-SHPRH. Pooled hazard ratio (HR) with 95% CI was applied to assess the prognostic value of circ-SHPRH. Results: Nine eligible studies, including 4 for diagnosis and 5 for prognosis, were included in this meta-analysis. Pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.79 (95% CI: 0.73–0.84), 0.75 (95% CI: 0.69–0.81), 3.20 (95% CI: 2.53–4.06), 0.28 (95% CI: 0.22–0.36), 11.27 (95% CI: 7.57–16.79), and 0.84 (95% CI: 0.80–0.87), respectively. Pooled HR indicated that low circ-SHPRH expression was significantly associated with poor overall survival (OS) (low vs high, HR=2.22, 95% CI: 1.60–3.09). Conclusion: The results of this meta-analysis indicate that circ-SHPRH might be an important diagnostic and prognostic biomarker for various solid cancers.
format Online
Article
Text
id pubmed-6549407
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65494072019-06-18 Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis Li, Feng Huang, Qilin Gong, Zhenyu Wang, Hongxiang Chen, Juxiang Onco Targets Ther Original Research Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for these solid cancers. Methods: Publications were searched in PubMed, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang database. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) (AUC) with 95% confidence interval (95% CI) were calculated to evaluate the diagnostic value of circ-SHPRH. Pooled hazard ratio (HR) with 95% CI was applied to assess the prognostic value of circ-SHPRH. Results: Nine eligible studies, including 4 for diagnosis and 5 for prognosis, were included in this meta-analysis. Pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.79 (95% CI: 0.73–0.84), 0.75 (95% CI: 0.69–0.81), 3.20 (95% CI: 2.53–4.06), 0.28 (95% CI: 0.22–0.36), 11.27 (95% CI: 7.57–16.79), and 0.84 (95% CI: 0.80–0.87), respectively. Pooled HR indicated that low circ-SHPRH expression was significantly associated with poor overall survival (OS) (low vs high, HR=2.22, 95% CI: 1.60–3.09). Conclusion: The results of this meta-analysis indicate that circ-SHPRH might be an important diagnostic and prognostic biomarker for various solid cancers. Dove 2019-05-31 /pmc/articles/PMC6549407/ /pubmed/31213850 http://dx.doi.org/10.2147/OTT.S200755 Text en © 2019 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Feng
Huang, Qilin
Gong, Zhenyu
Wang, Hongxiang
Chen, Juxiang
Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title_full Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title_fullStr Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title_full_unstemmed Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title_short Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
title_sort diagnostic and prognostic roles of circ-shprh for solid cancers: a meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549407/
https://www.ncbi.nlm.nih.gov/pubmed/31213850
http://dx.doi.org/10.2147/OTT.S200755
work_keys_str_mv AT lifeng diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis
AT huangqilin diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis
AT gongzhenyu diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis
AT wanghongxiang diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis
AT chenjuxiang diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis